Sunshine Biopharma's Total Assets for the quarter that ended in Dec. 2023 was $27.35 Mil.
During the past 12 months, Sunshine Biopharma's average Total Assets Growth Rate was 49.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 485.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 119.40% per year.
During the past 13 years, Sunshine Biopharma's highest 3-Year average Total Assets Growth Rate was 577.50%. The lowest was -46.60%. And the median was 178.45%.
The historical data trend for Sunshine Biopharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sunshine Biopharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (NAS:SBFM) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sunshine Biopharma's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sunshine Biopharma Total Assets Related Terms
Thank you for viewing the detailed overview of Sunshine Biopharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Sunshine Biopharma (Sunshine Biopharma) Business Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBFM has been successfully added to your 